A trio of employer groups has formed a new partnership to advocate for policies that address the problem of high—and growing—drug costs.
Employers are increasingly feeling the pressure of high drug costs, particularly as spending on high-cost biologics like adalimumab and etanercept continue to represent a significant share of spending despite comprising a relatively small proportion of total prescriptions. Drug spending is expected to keep rising alongside the dominance of specialty drugs, and so-called “super spenders,” or patients whose prescription drug costs exceed $250,000 per year, are growing in number.
It is against this backdrop that a trio of employer groups has formed a new partnership to advocate for policies that address the problem of high—and growing—drug costs. The Pacific Business Group on Health (PBGH), the ERISA Industry Committee, and the National Alliance of Healthcare Purchaser Coalitions this month announced a new initiative, called the Employers’ Prescription for Affordable Drugs, that they say seeks to drive the passage of legislation that will promote competition, transparency, and value in the marketplace. Collectively, the groups represent the largest purchaser of healthcare in the United States, purchasing care for more than 153 million individuals.
Among the policies that the new group supports are requiring pharmacy benefit managers (PBMs) to make pricing data available to payers, requiring PBMs to pass along savings from rebates, mandating that drug companies report and justify price increases for some drug products, and prohibiting conduct (such as PBM price spreading) that stifles competition from biosimilars and generics.
Other priorities for the group include requiring the FDA to publish patent information for biologics in the Purple Book, ending patent evergreening, halting “sham” citizen petitions to the FDA that can be used to delay competition, prohibiting pay-for-delay settlements, and preventing drug makers from using Risk Evaluation and Mitigation Strategy (REMS) programs to withhold samples needed for biosimilar and generic drug development.
The coalition also notes that capping price increases for drugs would result in overall savings, and price caps could be coupled with policies to limit drugs’ initial launch prices.
Two items of legislation expressly endorsed by the group are the Preserve Access to Affordable Generics and Biosimilars Act, which targets pay-for-delay deals, and the Lower Health Care Costs Act, which addresses abusive citizen petitions, allows generic and biosimilar developers to sue companies that withhold samples, and eliminates the requirement for a biosimilar or generic to use the same REMS program as the originator product’s sponsor.
In a statement, Elizabeth Mitchell, president and chief executive officer of PBGH, said that “Employers and patients are tired of bearing the brunt of high costs caused by a gamed system set up by drug manufacturers and pharmacy benefit managers. Employers are doing everything they can to contain costs, but this problem is too big to fix without action from the government.”
The launch of the coalition comes at a time when employers are increasingly recognizing their role in biosimilar adoption. Earlier this year, a report from Matrix Global Advisors and the National Business Group on Health used data from a large manufacturing company with a high-deductible plan to illustrate the fact that if biosimilars for common biologics are used half of the time at a 40% discount, the employer could save nearly $2 million each year.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.